FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
42 letters match. Newest first.
-
DrugsShoolin Pharma Chem LLP
Shoolin Pharma Chem, an Indian API maker, warned over filthy conditions, missing test data, and cleaning failures; all U.S. APIs recalled.
High risk -
DrugsSpa De Soleil, Inc.
FDA cites Spa De Soleil for CGMP violations in OTC topical drugs, including water system failures and missing component identity testing.
High risk -
DrugsGC America, Inc.
FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.
High risk -
DrugsSklar Personal Care Inc.
Sklar Personal Care’s drug facility failed CGMP (current good manufacturing practice), including untested raw materials and inadequate cleaning, process validation, and quality oversight.
High risk -
DrugsDeVere Manufacturing Inc.
FDA warned DeVere Manufacturing in Janesville, Wisconsin, that its OTC hand sanitizers are adulterated after a June 2025 inspection found CGMP failures.
High risk -
DrugsOwen Biosciences, Inc.
Owen Biosciences' over-the-counter benzoyl peroxide acne lotion had over 20 parts per million benzene and lacked release testing.
High risk -
DrugsDermaRite Industries, LLC
DermaRite failed CGMP and sold unapproved, misbranded OTC topical drugs, FDA says.
High risk -
DrugsABBE Laboratories, Inc.
FDA warns ABBE Laboratories over manufacturing failures for over-the-counter topical drugs, including ingredient testing.
High risk -
DrugsOasis Medical, Inc.
FDA cites Oasis Medical for current good manufacturing practice violations in sterile ophthalmic drugs, including particulate contamination and unresolved sterility failures.
High risk -
DrugsProduct Society LLC
FDA says Product Society LLC, an OTC drugmaker in North Hollywood, California, skipped identity testing for toxic DEG/EG and process validation.
High risk -
DrugsDyno Manufacturing, Inc.
Dyno Manufacturing’s OTC hand sanitizer and antibacterial soap drugs lacked raw-material identity testing and other required manufacturing controls.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsMicro Orgo Chem
Micro Orgo Chem in India failed CGMP for API drugs, including cleaning, process validation, stability and records.
High risk -
DrugsOutin Futures Corp.
FDA warned Outin Futures, a Korean drug manufacturer, of CGMP violations and sunscreen misbranding after a March 2024 inspection.
High risk -
DrugsClean Solutions LLC
FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.
High risk -
DrugsAerosol and Liquid Packaging, Inc.
FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.
High risk -
DrugsAvaria Health & Beauty Corp.
FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.
High risk -
DrugsKaylaan LLC
FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.
High risk -
DrugsGenuine Virgin Aloe Corp dba Triderma
FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.
High risk -
DrugsCosmetic Specialty Labs, Inc.
FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.
High risk -
DrugsColgin, Inc.
FDA warned Colgin that its OTC drug ChigaRid External Analgesic violated manufacturing quality rules, including expired ingredients and missing tests.
High risk -
DrugsColonial Dames Company, Ltd
FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.
High risk -
DrugsHandock Cosmetics Co., Ltd.
FDA warns Handock Cosmetics over manufacturing quality failures and unapproved/mislabeled hand sanitizers from South Korea.
High risk -
DrugsAvlon Industries, Inc.
FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.
High risk -
DrugsFuller Industries Inc.
FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.
High risk -
DrugsPremier Nutra Pharma Inc.
FDA cited Premier Nutra Pharma, a Carlsbad, California contract maker of nasal spray drugs, for CGMP violations after microbial contamination.
High risk -
DrugsZermat International S.A. de C.V.
FDA warns Zermat International about current good manufacturing practice violations for OTC drugs, including releasing out-of-specification lots without investigation.
High risk -
DrugsEco Lips, Inc.
FDA warned Eco Lips, Inc. that its over-the-counter sunscreen drug products had serious manufacturing and testing failures.
High risk -
DrugsCosmetic Science Laboratories LLC
FDA warned Cosmetic Science Laboratories about OTC sunscreen drugs made without required manufacturing controls.
High risk -
DrugsFormology Lab Inc.
FDA warned Formology Lab Inc. about manufacturing rule violations for drugs, including untested ingredients and unvalidated sunscreen processes.
High risk -
DrugsFrenda Corporation
FDA found Frenda made OTC alcohol and hand sanitizer under insanitary conditions with industrial chemical cross-contamination risk.
High risk -
DrugsAuto-Chlor System LLC
Auto-Chlor System LLC made hand sanitizer under poor manufacturing practices and sold it as an unapproved, misbranded new drug.
High risk -
DrugsKari Gran Inc.
Kari Gran Inc. released OTC SPF sunscreen drugs without adequate batch testing or stability data.
High risk -
DrugsAmerican Cleaning Solutions
FDA warned American Cleaning Solutions after a 2022 inspection found hand sanitizer made with inadequate cleaning, unvalidated processes, and substituted ethanol.
High risk -
DrugsSanitizer Supply LLC
FDA warns Sanitizer Supply LLC that its hand sanitizer wipes and sanitizers lacked required potency and microbial testing before release.
High risk -
DrugsVerde Cosmetic Labs LLC
FDA warned Verde Cosmetic Labs after an inspection found inadequate CGMP controls for OTC topical drugs, including cleaning and water system failures.
High risk -
DrugsGenlabs Corporation
FDA warns Genlabs Corporation of Chino, California, that its OTC hand soaps are adulterated and misbranded after finding serious CGMP failures.
High risk -
DrugsColorful Products Corporation
FDA warned Colorful Products Corporation about serious current good manufacturing practice (CGMP) failures for its over-the-counter topical drugs and hand sanitizers.
High risk -
DrugsSpecialty Process Labs LLC
FDA warned Specialty Process Labs about manufacturing quality failures for thyroid USP active ingredient, including unvalidated processes and data control gaps.
High risk -
DrugsAgropharma Laboratories, Inc.
FDA cited Agropharma Laboratories in Salinas, Puerto Rico, for serious manufacturing violations affecting its OTC antiseptics and hand sanitizers.
High risk -
DrugsNovel Laboratories, Inc. d.b.a LUPIN
FDA warned Lupin's Novel Laboratories over manufacturing violations including equipment cross-contamination and unvalidated temazepam capsules.
High risk -
DrugsYuyao YiJia Daily Chemical Co., Ltd.
Yuyao YiJia, a Chinese OTC drug and hand sanitizer maker, lacked finished-product, component and stability testing and an adequate quality unit.
High risk